losartan has been researched along with DDD MPGNII in 4 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Proteinuria is a common presentation of mesangioproliferative glomerulonephritis (MsPGN)." | 2.76 | Renin-angiotensin system inhibitors reduce the progression of mesangioproliferative glomerulonephritis: 10 year follow-up. ( Caglioti, C; Casoria, V; Comi, N; Conte, G; Fuiano, G; Fuiano, L; Iodice, C; Minutolo, R; Presta, P, 2011) |
| " Ligustrazine with the dosage of 80 mg twice a day was given to 25 patients in the treatment group by intravenous perfusion besides the medicine used in the control group." | 2.71 | [Effect of ligustrazine on proliferative glomerulonephritis]. ( Tang, X, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Presta, P | 1 |
| Minutolo, R | 1 |
| Iodice, C | 1 |
| Comi, N | 1 |
| Casoria, V | 1 |
| Fuiano, L | 1 |
| Caglioti, C | 1 |
| Conte, G | 1 |
| Fuiano, G | 1 |
| Tang, X | 1 |
| Ohtake, T | 1 |
| Oka, M | 1 |
| Maesato, K | 1 |
| Mano, T | 1 |
| Ikee, R | 1 |
| Moriya, H | 1 |
| Kobayashi, S | 1 |
| Peters, H | 1 |
| Border, WA | 1 |
| Noble, NA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis[NCT01115426] | Phase 4 | 20 participants (Actual) | Interventional | 1997-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for losartan and DDD MPGNII
| Article | Year |
|---|---|
Renin-angiotensin system inhibitors reduce the progression of mesangioproliferative glomerulonephritis: 10 year follow-up.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Di | 2011 |
[Effect of ligustrazine on proliferative glomerulonephritis].
Topics: Adolescent; Adult; Creatinine; Cyclophosphamide; Dipyridamole; Drug Therapy, Combination; Female; Fi | 2003 |
2 other studies available for losartan and DDD MPGNII
| Article | Year |
|---|---|
Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biopsy; Creatinine; Femal | 2008 |
Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade.
Topics: Angiotensin II; Animals; Blood Pressure; Body Weight; Eating; Enalapril; Fibronectins; Fibrosis; Glo | 1998 |